Teva has started over the past few months several collaborations with the Technion-Israel Institute of Technology regarding the development of new immunotherapy methods to treat cancer and diseases of the nervous system. Research teams from Teva and the Technion are conducting a joint study to test the effectiveness of innovative immunotherapy treatments using antibodies or cellular therapy in unique models of cancer, Parkinson's disease, and migraines.
According to Dr. Dana Bar-On, project leader and director of academic relations at Teva's Global R&D Department, "The collaboration with the Technion is one of the key building blocks of Teva's academic relations program – in Israel and around the world. After intensive mapping, we found leading researchers and partners in R&D at the Technion, even in the early stages. The combined force of academia and Teva is gaining momentum these days despite the delay caused by the spread of the coronavirus and the closure of some university activities. We believe the projects will advance in the coming years and some of them will be able to enter Teva's future pipeline."